vs
LivaNova PLC（LIVN）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是BRC Group Holdings, Inc.的1.9倍（$360.9M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 8.6%，领先39.4%），LivaNova PLC同比增速更快（12.1% vs -21.9%），过去两年LivaNova PLC的营收复合增速更高（10.6% vs -15.4%）
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
LIVN vs RILY — 直观对比
营收规模更大
LIVN
是对方的1.9倍
$188.3M
营收增速更快
LIVN
高出34.0%
-21.9%
净利率更高
RILY
高出39.4%
8.6%
两年增速更快
LIVN
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $360.9M | $188.3M |
| 净利润 | $30.9M | $90.3M |
| 毛利率 | 65.2% | 79.5% |
| 营业利润率 | 11.8% | 32.3% |
| 净利率 | 8.6% | 47.9% |
| 营收同比 | 12.1% | -21.9% |
| 净利润同比 | -44.7% | 1710.8% |
| 每股收益（稀释后） | $0.57 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIVNRILY
| Q4 25 | $360.9M | $188.3M | ||
| Q3 25 | $357.8M | $215.3M | ||
| Q2 25 | $352.5M | $188.2M | ||
| Q1 25 | $316.9M | $197.2M | ||
| Q4 24 | $321.8M | $241.0M | ||
| Q3 24 | $318.1M | $225.5M | ||
| Q2 24 | $318.6M | $256.0M | ||
| Q1 24 | $294.9M | $263.4M |
净利润LIVNRILY
| Q4 25 | $30.9M | $90.3M | ||
| Q3 25 | $26.8M | $91.1M | ||
| Q2 25 | $27.2M | $139.5M | ||
| Q1 25 | $-327.3M | $-10.0M | ||
| Q4 24 | $55.9M | $-5.6M | ||
| Q3 24 | $33.0M | $-284.4M | ||
| Q2 24 | $16.3M | $-433.6M | ||
| Q1 24 | $-41.9M | $-49.2M |
毛利率LIVNRILY
| Q4 25 | 65.2% | 79.5% | ||
| Q3 25 | 68.4% | 83.7% | ||
| Q2 25 | 67.8% | 81.3% | ||
| Q1 25 | 69.7% | 81.4% | ||
| Q4 24 | 68.2% | 79.8% | ||
| Q3 24 | 70.8% | 82.1% | ||
| Q2 24 | 68.7% | 84.5% | ||
| Q1 24 | 70.3% | 85.3% |
营业利润率LIVNRILY
| Q4 25 | 11.8% | 32.3% | ||
| Q3 25 | 15.1% | 30.4% | ||
| Q2 25 | 15.4% | 5.7% | ||
| Q1 25 | 15.3% | -31.2% | ||
| Q4 24 | 11.5% | -69.2% | ||
| Q3 24 | 11.2% | -36.4% | ||
| Q2 24 | 12.6% | -90.8% | ||
| Q1 24 | 5.5% | -6.1% |
净利率LIVNRILY
| Q4 25 | 8.6% | 47.9% | ||
| Q3 25 | 7.5% | 42.3% | ||
| Q2 25 | 7.7% | 74.1% | ||
| Q1 25 | -103.3% | -5.1% | ||
| Q4 24 | 17.4% | -2.3% | ||
| Q3 24 | 10.4% | -126.1% | ||
| Q2 24 | 5.1% | -169.4% | ||
| Q1 24 | -14.2% | -18.7% |
每股收益（稀释后）LIVNRILY
| Q4 25 | $0.57 | $2.78 | ||
| Q3 25 | $0.49 | $2.91 | ||
| Q2 25 | $0.50 | $4.50 | ||
| Q1 25 | $-6.01 | $-0.39 | ||
| Q4 24 | $1.04 | $-0.01 | ||
| Q3 24 | $0.60 | $-9.39 | ||
| Q2 24 | $0.30 | $-14.35 | ||
| Q1 24 | $-0.78 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.6M | $226.6M |
| 总债务越低越好 | $376.1M | $1.4B |
| 股东权益账面价值 | $1.2B | $-171.5M |
| 总资产 | $2.6B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资LIVNRILY
| Q4 25 | $635.6M | $226.6M | ||
| Q3 25 | $646.1M | $184.2M | ||
| Q2 25 | $593.6M | $267.4M | ||
| Q1 25 | $738.4M | $138.3M | ||
| Q4 24 | $428.9M | $146.9M | ||
| Q3 24 | $346.4M | $159.2M | ||
| Q2 24 | $329.2M | $236.9M | ||
| Q1 24 | $309.2M | $190.7M |
总债务LIVNRILY
| Q4 25 | $376.1M | $1.4B | ||
| Q3 25 | $434.5M | $1.3B | ||
| Q2 25 | $430.6M | $1.3B | ||
| Q1 25 | $628.2M | $1.4B | ||
| Q4 24 | $627.0M | $1.5B | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
股东权益LIVNRILY
| Q4 25 | $1.2B | $-171.5M | ||
| Q3 25 | $1.2B | $-260.5M | ||
| Q2 25 | $1.1B | $-351.7M | ||
| Q1 25 | $1.0B | $-496.8M | ||
| Q4 24 | $1.3B | $-488.2M | ||
| Q3 24 | $1.3B | $-497.6M | ||
| Q2 24 | $1.2B | $-218.3M | ||
| Q1 24 | $1.2B | $228.4M |
总资产LIVNRILY
| Q4 25 | $2.6B | $1.7B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.6B | $1.5B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.5B | $5.0B |
负债/权益比LIVNRILY
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $50.2M | — |
| 自由现金流率自由现金流/营收 | 13.9% | — |
| 资本支出强度资本支出/营收 | 8.9% | — |
| 现金转化率经营现金流/净利润 | 2.67× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $173.3M | — |
8季度趋势，按日历期对齐
经营现金流LIVNRILY
| Q4 25 | $82.4M | $26.2M | ||
| Q3 25 | $85.1M | $-60.6M | ||
| Q2 25 | $62.9M | $-25.6M | ||
| Q1 25 | $24.0M | $184.0K | ||
| Q4 24 | $78.7M | $-2.7M | ||
| Q3 24 | $51.0M | $19.5M | ||
| Q2 24 | $43.4M | $111.5M | ||
| Q1 24 | $10.0M | $135.4M |
自由现金流LIVNRILY
| Q4 25 | $50.2M | — | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $47.8M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $68.3M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $31.2M | — | ||
| Q1 24 | $3.6M | — |
自由现金流率LIVNRILY
| Q4 25 | 13.9% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 1.2% | — |
资本支出强度LIVNRILY
| Q4 25 | 8.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 2.2% | — |
现金转化率LIVNRILY
| Q4 25 | 2.67× | 0.29× | ||
| Q3 25 | 3.18× | -0.66× | ||
| Q2 25 | 2.32× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
